Please login to the form below

Not currently logged in
Email:
Password:

GLP-1 agonists

This page shows the latest GLP-1 agonists news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk shareholder revolt reaches Europe

Novo Nordisk shareholder revolt reaches Europe

Novo Nordisk has latterly become less reliant on sales of its insulin products as newer products, particularly GLP-1 agonists Victoza (liraglutide) and Ozempic (semaglutide), have increased their share of revenues.

Latest news

  • Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12% Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

    Lilly revealed last November that the top-line data with the once-weekly GLP-1 agonist was positive, and over the weekend at the American Diabetes Association meeting, presented the detailed ... Trulicity's growth to date has stemmed largely from its once

  • Novo's semaglutide beats Lilly's Trulicity in diabetes contest Novo's semaglutide beats Lilly's Trulicity in diabetes contest

    Novo Nordisk says its once-weekly GLP-1 agonist semaglutide could become a "new standard" in type 2 diabetes after beating rival Eli Lilly's Trulicity (dulaglutide) in a phase III ... Trulicity's growth stems from its once-weekly dosing, which has proved

  • Sanofi's lixisenatide is back under FDA review Sanofi's lixisenatide is back under FDA review

    In the interim Novo Nordisk's rival Victoza (liraglutide) has firmly established itself at the top of the GLP-1 agonist tree, with sales of around $2bn a year. ... Meanwhile, new GLP-1 agonists that require dosing just once a week - including Eli Lilly's

  • Sanofi plans LixiLan filings after positive phase III trial Sanofi plans LixiLan filings after positive phase III trial

    If approved it will compete in the market with Novo Nordisk's insulin/GLP-1 agonist product Xultophy (insulin degludec/liraglutide), which was launched earlier this year. ... Jefferies' Peter Wellford indicating earlier this year that the basal

  • Novo Nordisk's Victoza fails type 1 diabetes trial Novo Nordisk's Victoza fails type 1 diabetes trial

    The year-long trial involved almost 1, 400 patients who were given one of three doses of long-acting GLP-1 agonist liraglutide or placebo, given once-daily by subcutaneous injection - ... episodes. The concept of combining insulin with GLP-1 agonists has

More from news
Approximately 8 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics